US Stock MarketDetailed Quotes
SHTDY SINOPHARM GROUP CO
Watchlist
12.310
+0.190+1.57% Close 11/30 16:00 ET
12.370High12.300Low14.04KVolume
12.355Open12.120Pre Close172.92KTurnover0.00%Turnover Ratio6.40P/E (TTM)7.68BMarket Cap17.40452wk High6.22P/E (Static)624.13MShares11.20952wk Low0.78P/B7.68BFloat Cap24.356Historical High0.57Dividend TTM624.13MShs Float7.620Historical Low4.64%Div YieldTTM0.58%Amplitude12.318Avg Price1Lot Size
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SINOPHARM GROUP CO Stock Forum
$AMC Entertainment(AMC.US)$$SINOPHARM(01099.HK)$$Kweichow Moutai(600519.SH)$$Alibaba(BABA.US)$$TENCENT(00700.HK)$$JD.com(JD.US)$$Sheng Siong(OV8.SG)$$UOB(U11.SG)$$Singtel(Z74.SG)$$BioNTech(BNTX.US)$$Sea(SE.US)$
Sinopharm is principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is en...
DBS: China Healthcare Sector – Pharmaceutical Packaging
$MICROPORT(00853.HK)$$WEIGAO GROUP(01066.HK)$$CSPC PHARMA(01093.HK)$$SINOPHARM(01099.HK)$$CR MEDICAL(01515.HK)$$CONSUN PHARMA(01681.HK)$$CHUNLI MEDICAL(01858.HK)$$UNI MEDICAL(02666.HK)$$HENLIUS(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$BEIGENE(06160.HK)$
DBS: SINOPHARM GROUP CO LTD – Buy Target Price HK$30.00
$SINOPHARM(01099.HK)$
DBS: China Biotech Sector
$BEIGENE(06160.HK)$$CSPC PHARMA(01093.HK)$$HENLIUS(02696.HK)$$MICROPORT(00853.HK)$$WEIGAO GROUP(01066.HK)$$SINOPHARM(01099.HK)$$CR MEDICAL(01515.HK)$$CONSUN PHARMA(01681.HK)$$CHUNLI MEDICAL(01858.HK)$$UNI MEDICAL(02666.HK)$$HENLIUS(02696.HK)$$B-Soft Co.,Ltd.(300451.SZ)$$Guangxi LiuYao Group(603368.SH)$$BEIGENE(06160.HK)$
KGI: Sinopharm Group Co., Ltd. (1099 HK) – A defensive counter amidst sell-off
$SINOPHARM(01099.HK)$
J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -stud
The Omicron variant has raised concerns regarding its ability to evade protection provided by widely-used vaccines, with drugmakers tailoring their shots to target the variant while testing the effectiveness of their existing shots.
Vaccines from $Moderna(MRNA.US)$ , $ASTRAZENECA(AZNCF.US)$ and $Pfizer(PFE.US)$ and partner $BioNTech(BNTX.US)$ retained activity against Omicron, but the antibody response was greatly reduced when compared with the original virus strain first detected in China, the study found.
The study also found that while the effectiveness of $GlaxoSmithKline(GSK.US)$ and Vir Biotech's COVID-19 drug sotrovimab reduced three-fold against Omicron compared to the original strain, monoclonal antibody treatments by Regeneron and Eli Lilly completely lost their neutralizing activity against the variant.
The finding is consistent with recent laboratory tests demonstrating the two treatments lose most of their effectiveness when exposed to the Omicron variant.
No comment yet